Sentinel node biopsy for breast cancer larger than 3 cm in diameter
2007 (English)In: British Journal of Surgery, ISSN 0007-1323, E-ISSN 1365-2168, Vol. 94, no 8, 948-951 p.Article in journal (Refereed) Published
Background:Sentinel node biopsy (SNB) is a standard staging procedure in early breast cancer. Its suitability for larger tumours has been questioned. This study evaluated the reliability of SNB in women with invasive breast cancer larger than 3 cm in diameter who were clinically axillary node negative.Methods:Some 109 women with a tumour larger than 3 cm on pathological analysis were identified from the Swedish prospective SNB database. They were included if a completion axillary clearance was planned, regardless of SNB results.Results:The sentinel node detection rate was 103 (94·5 per cent) of 109. The overall false-negative rate was eight (13 per cent) of 64. Although a preoperative diagnosis of multifocal tumour was an exclusion criterion, 16 such cases were revealed on postoperative pathological examination. The false-negative rate in this subgroup was higher than that in women with a unifocal tumour (four (31 per cent) of 13 versus four (8 per cent) of 51; P = 0·012). No other significant predictors of a false-negative sentinel node biopsy were identified.Conclusion:SNB is feasible in patients with unifocal breast tumours larger than 3 cm. When large tumour size coincides with multifocality, however, the false-negative rate seems to be increased and a completion axillary clearance should be considered even if the SNB is negative.
Place, publisher, year, edition, pages
2007. Vol. 94, no 8, 948-951 p.
Mammary gland diseases, Breast cancer, Treatment, Surgery, Medicine, Diameter, Mammary gland, Anatomic pathology, Biopsy, Sentinel lymph node, Malignant tumor
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-95904DOI: 10.1002/bjs.5713ISI: 000248921700006PubMedID: 17436338OAI: oai:DiVA.org:uu-95904DiVA: diva2:170279